Skin Cancer

Faculty at the Dermatology Times Cutaneous Oncology Workshop addressed real-world questions on mole mapping, biopsy decisions, oral photoprotection, and actinic keratosis treatment.

In the morning session, Experts highlighted evolving photoprotection strategies, field-directed treatment of actinic keratoses, hereditary cancer risk, and practical dermoscopy pearls for APPs.

Dermatology Times kicks off its first Cutaneous Oncology Workshop, bringing APPs and experts together for practical skin cancer education.

Advanced practice providers will gather September 12 for a full-day program covering skin cancer prevention, diagnosis, staging, treatment, and procedural skills.

Shawn Demehri, MD, PhD, discusses a calcipotriene/5-FU combination immunotherapy for field cancerization and its potential in organ transplant recipients.

Experts map referral pathways and team-based immunotherapy care for advanced cutaneous squamous cell carcinoma, tackling toxicity and follow-up gaps.

Experts weigh checkpoint inhibitors for advanced cutaneous squamous cell carcinoma, highlighting real-world safety, immunotherapy referrals, and where cosibelimab may belong.

Multidisciplinary experts rethink advanced cutaneous squamous cell carcinoma care, weighing immunotherapy options, trial data limits, adverse events, and smoother dermatology-oncology referrals.

The latest DermView custom video series explored how molecular tools are reshaping management decisions in cutaneous squamous cell carcinoma.

Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.

Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.

Phase 3 data from Merck and Moderna show mRNA vaccine intismeran plus pembrolizumab cuts melanoma relapse and spread after surgery, hinting at new adjuvant standard.

New research shows dermatologists continue to back daily sunscreen to prevent aging and skin cancer, debunking viral myths and spotlighting safer new filters coming to the US.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

In the August letter from the editor in chief, Christopher Bunick, MD, PhD, explains bemotrizinol’s broad-spectrum UVA/UVB benefits and simple UV safety habits for sunscreen, pools, and wounds.

An MCC case illustrates how travel distance and limited oncology access can influence treatment decisions and adherence in rural patients.

FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.

The accelerated FDA approval, based on Replimune's phase 2 IGNYTE trial data, gives clinicians a new second-line option for adults with advanced melanoma progressing after anti-PD-1 therapy.

As we wrap up UV Safety Awareness Month, Kathleen Suozzi, MD, explains warning signs of sun damage, sunscreen myths, and new year-round protection tools—plus the newly FDA-approved bemotrizinol.

As we wrap up July, explore the new sunscreen ingredient approval, debunk summer skin care myths, and learn how UV damage and therapies are shaping skin cancer prevention today.

Our July issue tackles melanoma surgery challenges, melasma in skin of color, new bemotrizinol sunscreen, atopic dermatitis breakthroughs, and billing insights from Whitney Hovenic, MD, Joseph Gatti, DMSc, Rivkah Epstein, PA-C, and more.

New trends around cheeky swimwear and tanning myths are leading to rising rates of melanomas in sensitive areas; read July's cover story to learn more.

Long-term TNF inhibitor use was associated with significantly increased risks of melanoma and nonmelanoma skin cancer in a large cohort study.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Boston compared immunotherapy selection, referral practices and surveillance strategies in advanced cutaneous squamous cell carcinoma.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Dallas compared immunotherapy selection, adverse event management, and referral practices in advanced cutaneous squamous cell carcinoma.